ARMANDO ANIDO

CIK 1219866 · Chairman & Chief Exec. Officer · last filed 2025-06-30

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$17.66M

Companies

7

Total Filings

70

Lifetime Open-Market Net

-$3.54M

Filer Profile

Reported Address
1 EVERTRUST PLAZA
13TH FLOOR
JERSEY CITY, NJ 07302
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SCYX Director 8,875 $4.84 $43.0K $31.2K 11 2025-06-30
Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Chairman & Chief Exec. Officer 0 $1.30 $0 $130.0K 17 2023-10-11
AVIR Director $5.31 $0 2 2017-05-22
Vaxart, Inc. (BOTA) Delisted Director $0 1 2015-10-21
PATH Chief Executive Officer 1,270,000 $13.75 $17.46M $0 4 2013-01-22
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted CEO & President 77,267 -$3.71M 26 2011-10-11
RPRX Director 2,612 $58.61 $153.1K $0 5 2010-05-19

Recent Filings · Page 7 of 7

70 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2009-01-07 RPRX Grant (A) $0 EDGAR
2008-09-12 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Gift (G) $0 EDGAR
2008-07-21 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Tax (F) −16,032 -$595.9K EDGAR
2008-07-17 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Tax (F) −12,044 -$195.7K EDGAR
2008-05-27 RPRX Grant (A) +1,419 $0 EDGAR
2008-03-05 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Grant (A) $0 EDGAR
2008-02-26 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Grant (A) $0 EDGAR
2007-11-02 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Grant (A) $0 EDGAR
2007-05-18 RPRX Grant (A) +1,319 $0 EDGAR
2007-02-27 AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Grant (A) $0 EDGAR
Showing 6170 of 70
Page 7 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.